185 related articles for article (PubMed ID: 26110620)
1. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
2. Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway.
Liu J; Luo B; Zhao M
Mol Med Rep; 2017 Dec; 16(6):7949-7958. PubMed ID: 28983587
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Yang YT; Yuzbasiyan-Gurkan V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012610
[TBL] [Abstract][Full Text] [Related]
4. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
5. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
6. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
8. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
9. Expression of the hedgehog signalling pathway and the effect of inhibition at the level of smoothened in canine osteosarcoma cell lines.
Nam A; Song WJ; An JH; Rebhun RB; Youn HY; Seo KW
Vet Comp Oncol; 2022 Dec; 20(4):778-787. PubMed ID: 35521940
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.
Lopez CM; Yu PY; Zhang X; Yilmaz AS; London CA; Fenger JM
PLoS One; 2018; 13(1):e0190086. PubMed ID: 29293555
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of P16 expression in canine appendicular osteosarcoma.
Murphy BG; Mok MY; York D; Rebhun R; Woolard KD; Hillman C; Dickinson P; Skorupski K
BMC Vet Res; 2017 Jun; 13(1):189. PubMed ID: 28633676
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of canonical Hedgehog signaling pathway inhibition in canine osteosarcoma.
Baldanza VE; Rogic A; Yan W; Levine CB; Levine RA; Miller AD; McCleary-Wheeler AL
PLoS One; 2020; 15(4):e0231762. PubMed ID: 32348319
[TBL] [Abstract][Full Text] [Related]
13. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic action of Brazilian propolis in vitro on canine osteosarcoma cells.
Cinegaglia NC; Bersano PR; Búfalo MC; Sforcin JM
Phytother Res; 2013 Sep; 27(9):1277-81. PubMed ID: 23074147
[TBL] [Abstract][Full Text] [Related]
15. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
16. ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma.
Cam M; Gardner HL; Roberts RD; Fenger JM; Guttridge DC; London CA; Cam H
Oncotarget; 2016 Jul; 7(30):48533-48546. PubMed ID: 27391430
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.
Mackowiak da Fonseca J; Mackowiak da Fonseca II; Nagamine MK; Massoco CO; Nishiya AT; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987941
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
19. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
20. Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy.
Asling J; Morrison J; Mutsaers AJ
Cell Stress Chaperones; 2016 Nov; 21(6):1065-1076. PubMed ID: 27631331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
